Blueprint Medicines Corporation
Informe acción NasdaqGS:BPMC
Capitalización de mercado: US$6.4b
Blueprint Medicines Crecimiento futuro
Future controles de criterios 6/6 Se prevé un crecimiento anual de los beneficios y los ingresos de Blueprint Medicines de 68.9% y 25.3% por año respectivamente. Se prevé que el BPA crezca en un 68.8% al año. Se espera que la rentabilidad financiera sea de 47% en 3 años.
Información clave
68.9%
Tasa de crecimiento de los beneficios
68.8%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Biotechs 27.3% Tasa de crecimiento de los ingresos 25.3% Rentabilidad financiera futura 47.0% Cobertura de analistas Good
Última actualización 31 Oct 2024
Actualizaciones recientes sobre el crecimiento futuro
Consensus estimates of losses per share improve by 19% Nov 06
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024 Nov 02
Consensus revenue estimates increase by 14% Aug 08
No longer forecast to breakeven Aug 02
Blueprint Medicines Corporation Raises Revenue Guidance for the Full Year 2024 Aug 01
Consensus revenue estimates increase by 10% May 09
Mostrar todas las actualizaciones
Chairman notifies of intention to sell stock Nov 08
Consensus estimates of losses per share improve by 19% Nov 06
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024 Nov 02
Third quarter 2024 earnings: EPS exceeds analyst expectations Nov 01
Blueprint Medicines Corporation to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
Blueprint Medicines: Growth For The Long Term Still Mostly Priced In Sep 27
Chairman notifies of intention to sell stock Sep 11
Chief Financial Officer notifies of intention to sell stock Aug 18
Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt? Aug 16
Consensus revenue estimates increase by 14% Aug 08
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 02
No longer forecast to breakeven Aug 02
Blueprint Medicines Corporation Raises Revenue Guidance for the Full Year 2024 Aug 01
Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S Jul 23
Blueprint Medicines Corporation to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
Blueprint Medicines: Overdue For A Breather Jul 16
Chief People Officer exercised options and sold US$724k worth of stock Jul 09
Chief People Officer notifies of intention to sell stock Jun 23
Chief Scientific Officer recently sold US$421k worth of stock Jun 10
Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting May 24
Senior VP notifies of intention to sell stock May 17
Consensus revenue estimates increase by 10% May 09
Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year May 05
Blueprint Medicines: Rampant Growth Mostly Priced In May 04 Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024 May 03
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 03
Blueprint Medicines Corporation, Annual General Meeting, Jun 12, 2024 Apr 28
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way? Apr 26
Blueprint Medicines Corporation to Report Q1, 2024 Results on May 02, 2024 Apr 20
Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC) Apr 05
Chief Financial Officer notifies of intention to sell stock Mar 18
President recently sold US$1.1m worth of stock Mar 13
Insider notifies of intention to sell stock Mar 01
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting Feb 24
Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade) Feb 20
New minor risk - Shareholder dilution Feb 16
Forecast to breakeven in 2026 Feb 16
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024 Feb 15
Blueprint Medicines Corporation to Report Q4, 2023 Results on Feb 15, 2024 Feb 02
Chairman notifies of intention to sell stock Jan 28
Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate Jan 08
Senior VP notifies of intention to sell stock Dec 22
Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38% Dec 18
Blueprint Medicines' Ayvakyt (Avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis Dec 13
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted At 2023 Ash Annual Meeting Dec 11
Insider notifies of intention to sell stock Dec 10
Chairman notifies of intention to sell stock Nov 27
Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load? Nov 20
Blueprint Medicines' Ayvakyt (Avapritinib) Receives Positive Chmp Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis Nov 12
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Oct 27
New minor risk - Share price stability Oct 26
Blueprint Medicines Corporation to Report Q3, 2023 Results on Oct 26, 2023 Oct 13
Chairman exercised options and sold US$1.2m worth of stock Oct 01
Chairman notifies of intention to sell stock Aug 27
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 03
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly? Jul 26
Blueprint Medicines Announces Clinical Data for Multiple Programs Across its Precision Therapy Portfolio at the 2023 American Society of Clinical Oncology Jun 04
Blueprint Medicines Corporation Announces NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT (avapritinib) in Patients with Indolent Systemic Mastocytosis May 24
Blueprint Medicines Corporation Announces U.S. Food and Drug Administration Approves AYVAKIT(R) (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis May 23
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 06
Blueprint Medicines Corporation Provides Revenue Guidance for the Year 2023 May 05
Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt? Apr 16
Insider recently sold US$77k worth of stock Mar 10
Price target decreased by 8.1% to US$69.41 Feb 17
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year of 2023 Feb 17
Blueprint Medicines Corporation Announces Partial Clinical Hold for Phase 1/2 Vela Trial of Blu-222 Feb 11
Blueprint Medicines Corporation to Report Q4, 2022 Results on Feb 16, 2023 Feb 10
Blueprint Medicines Corporation Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT(R) Jan 24
Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value Jan 09
Blueprint Medicines Corporation Announces Board Changes Jan 07
Blueprint Medicines Corporation Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis Dec 12
Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt Dec 12
Executive Chairman notifies of intention to sell stock Dec 09
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (Avapritinib) for the Treatment of Indolent Systemic Mastocytosis Nov 23
Price target decreased to US$78.75 Nov 16
Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates Nov 07
Price target decreased to US$82.19 Nov 03
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 02
Blueprint Medicines Corporation Provides Revenue Guidance for 2022 Nov 02
President of Research & Development recently sold US$234k worth of stock Oct 08
Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal Sep 15
Blueprint Medicines Corporation Announces CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis Aug 25
Executive Chairman notifies of intention to sell stock Aug 20
Blueprint Medicines Announces Positive Top-Line Results from Pioneer Trial of AYVAKIT® (Avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints Aug 18
Blueprint to seek label expansion for systemic mastocytosis therapy after trial win Aug 17
Executive Chairman exercised options and sold US$632k worth of stock Aug 13
Insider recently sold US$314k worth of stock Aug 10
Consensus EPS estimates fall by 10% Aug 09
Insider notifies of intention to sell stock Aug 08
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 03
Blueprint Medicines Corporation Provides Revenue Guidance for 2022 Aug 03
Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance Aug 02 Blueprint Medicines Corporation announced that it expects to receive $400 million in funding from Sixth Street Partners Jul 02
Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront Jun 30
Price target decreased to US$91.87 Jun 27
Previsiones de crecimiento de beneficios e ingresos NasdaqGS:BPMC - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions) Fecha Ingresos Beneficios Flujo de caja libre Flujo de caja operativo Núm. de analistas medio 12/31/2026 949 86 98 228 17 12/31/2025 712 -84 -30 43 17 12/31/2024 508 -74 -205 58 17 9/30/2024 434 -128 -251 -242 N/A 6/30/2024 363 -205 -348 -333 N/A 3/31/2024 282 -288 -430 -415 N/A 12/31/2023 249 -507 -453 -437 N/A 9/30/2023 216 -555 -492 -479 N/A 6/30/2023 226 -554 -515 -505 N/A 3/31/2023 205 -581 -503 -493 N/A 12/31/2022 204 -558 -511 -502 N/A 9/30/2022 272 -718 -404 -395 N/A 6/30/2022 230 -702 -367 -361 N/A 3/31/2022 221 -650 -310 -306 N/A 12/31/2021 180 -644 -302 -299 N/A 9/30/2021 107 -411 -312 -309 N/A 6/30/2021 828 340 407 409 N/A 3/31/2021 809 325 369 371 N/A 12/31/2020 794 314 384 387 N/A 9/30/2020 811 333 361 367 N/A 6/30/2020 75 -395 -340 -327 N/A 3/31/2020 72 -371 -321 -307 N/A 12/31/2019 67 -348 -292 -278 N/A 9/30/2019 16 -362 -311 -301 N/A 6/30/2019 8 -340 -291 -284 N/A 3/31/2019 44 -267 -214 -206 N/A 12/31/2018 45 -237 -188 -175 N/A 9/30/2018 45 -205 -165 -142 N/A 6/30/2018 52 -170 N/A -114 N/A 3/31/2018 17 -177 N/A -138 N/A 12/31/2017 21 -148 N/A -120 N/A 9/30/2017 27 -120 N/A -104 N/A 6/30/2017 26 -99 N/A -96 N/A 3/31/2017 27 -85 N/A -86 N/A 12/31/2016 28 -72 N/A -25 N/A 9/30/2016 25 -67 N/A -19 N/A 6/30/2016 22 -63 N/A -13 N/A 3/31/2016 18 -58 N/A -6 N/A 12/31/2015 11 -56 N/A -32 N/A 9/30/2015 7 -57 N/A -30 N/A 6/30/2015 3 -56 N/A -26 N/A 3/31/2015 1 -52 N/A -24 N/A 12/31/2014 N/A -46 N/A -35 N/A
Mostrar más
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que BPMC sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).
Beneficios vs. Mercado: Se prevé que BPMC sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que BPMC sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (25.3% al año) de BPMC crezcan más rápidamente que los del mercado US (8.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (25.3% al año) de BPMC crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de BPMC sea muy elevada dentro de 3 años (47%).
Descubre empresas en crecimiento Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
